Biomarker-Based Signature of Alzheimer’s Disease in Pre-MCI Individuals
Abstract
:Literature Search: Selection Criteria
1. Introduction: the Complicated Picture of What Precedes Mild Cognitive Impairment
1.1. Pre-MCI: Conceptual Evolution and Clinical Issues
1.2. Neuropathological Studies
2. Pre-MCI: Neuropsychological and Biomarkers Findings
2.1. Neuropsychological Characterization
2.1.1. Subtle Cognitive Decline: What “Subtle” Stands For
2.1.2. Subtle Cognitive Decline: What “Cognitive” Stands For
2.1.3. Subtle Cognitive Decline: What “Decline” Stands For
2.2. Pathophysiological Biomarkers
2.2.1. CSF
2.2.2. Amyloid PET
2.3. Topographical Biomarkers
2.3.1. FDG-PET
2.3.2. MRI
3. Discussion
4. Conclusions
Author Contributions
Funding
Acknowledgments
Conflicts of Interest
References
- Dubois, B.; Hampel, H.; Feldman, H.H.; Scheltens, P.; Aisen, P.; Andrieu, S.; Broich, K.; Bakardjian, H.; Benali, H.; Bertram, L.; et al. Preclinical Alzheimer’s disease: Definition, natural history, and diagnostic criteria. Alzheimer Dement. 2016, 12, 292–323. [Google Scholar] [CrossRef] [PubMed]
- McKhann, G.M.; Knopman, D.S.; Chertkow, H.; Hyman, B.T.; Jack, C.R.; Kawas, C.H.; Klunk, W.E.; Koroshetz, W.J.; Manly, J.J.; Mayeux, R.; et al. The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimer Dement. 2011, 7, 263–269. [Google Scholar] [CrossRef] [PubMed]
- Dubois, B.; Feldman, H.H.; Jacova, C.; Hampel, H.; Molinuevo, J.L.; Blennow, K.; DeKosky, S.T.; Gauthier, S.; Selkoe, D.; Bateman, R.; et al. Advancing research diagnostic criteria for Alzheimer’s disease: The IWG-2 criteria. Lancet Neurol. 2014, 13, 614–629. [Google Scholar] [CrossRef]
- Jack, C.R., Jr.; Bennett, D.A.; Blennow, K.; Carrillo, M.C.; Feldman, H.H.; Frisoni, G.B.; Hampel, H.; Jagust, W.J.; Johnson, K.A.; Knopman, D.S.; et al. A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology 2016, 87, 539–547. [Google Scholar] [CrossRef] [PubMed]
- Jack, C.R.; Bennett, D.A.; Blennow, K.; Carrillo, M.C.; Dunn, B.; Haeberlein, S.B.; Holtzman, D.M.; Jagust, W.; Jessen, F.; Karlawish, J.; et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease. Alzheimer Dement. 2018, 14, 535–562. [Google Scholar] [CrossRef] [PubMed]
- Hyman, B.T.; Phelps, C.H.; Beach, T.G.; Bigio, E.H.; Cairns, N.J.; Carrillo, M.C.; Dickson, D.W.; Duyckaerts, C.; Frosch, M.P.; Masliah, E.; et al. National Institute on Aging-Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease. Alzheimer Dement. 2012, 8, 1–13. [Google Scholar] [CrossRef]
- Petersen, R.C.; Doody, R.; Kurz, A.; Mohs, R.C.; Morris, J.C.; Rabins, P.V.; Ritchie, K.; Rossor, M.; Thal, L.; Winblad, B. Current concepts in mild cognitive impairment. Arch. Neurol. 2001, 58, 1985–1992. [Google Scholar] [CrossRef]
- Winblad, B.; Palmer, K.; Kivipelto, M.; Jelic, V.; Fratiglioni, L.; Wahlund, L.-O.; Nordberg, A.; Bäckman, L.; Albert, M.; Almkvist, O.; et al. Mild cognitive impairment--beyond controversies, towards a consensus: Report of the International Working Group on Mild Cognitive Impairment. J. Intern. Med. 2004, 256, 240–246. [Google Scholar] [CrossRef]
- Albert, M.S.; DeKosky, S.T.; Dickson, D.; Dubois, B.; Feldman, H.H.; Fox, N.C.; Gamst, A.; Holtzman, D.M.; Jagust, W.J.; Petersen, R.C.; et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on. Alzheimer Dement. 2011, 7, 270–279. [Google Scholar] [CrossRef]
- Dubois, B.; Feldman, H.H.; Jacova, C.; Cummings, J.L.; DeKosky, S.T.; Barberger-Gateau, P.; Delacourte, A.; Frisoni, G.; Fox, N.C.; Galasko, D.; et al. Revising the definition of Alzheimer’s disease: A new lexicon. Lancet Neurol. 2010, 9, 1118–1127. [Google Scholar] [CrossRef]
- Sperling, R.A.; Aisen, P.S.; Beckett, L.A.; Bennett, D.A.; Craft, S.; Fagan, A.M.; Iwatsubo, T.; Jack, C.R., Jr.; Kaye, J.; Park, D.C.; et al. Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimer Dement. 2011, 7, 280–292. [Google Scholar] [CrossRef] [PubMed]
- Parnetti, L.; Chipi, E.; Salvadori, N.; D’Andrea, K.; Eusebi, P. Prevalence and risk of progression of preclinical Alzheimer’s disease stages: A systematic review and meta-analysis. Alzheimer Res. Ther. 2019, 11, 7. [Google Scholar] [CrossRef] [PubMed]
- Storandt, M.; Grant, E.A.; Miller, J.P.; Morris, J.C. Longitudinal course and neuropathologic outcomes in original vs revised MCI and in pre-MCI. Neurology 2006, 67, 467–473. [Google Scholar] [CrossRef] [PubMed]
- Baker, J.E.; Lim, Y.Y.; Pietrzak, R.H.; Hassenstab, J.; Snyder, P.J.; Masters, C.L.; Maruff, P. Cognitive impairment and decline in cognitively normal older adults with high amyloid-β: A meta-analysis. Alzheimer Dement. 2017, 6, 108–121. [Google Scholar] [CrossRef] [PubMed]
- Duara, R.; Loewenstein, D.A.; Greig, M.T.; Potter, E.; Barker, W.; Raj, A.; Schinka, J.; Borenstein, A.; Schoenberg, M.; Wu, Y.; et al. Pre-MCI and MCI: Neuropsychological, clinical, and imaging features and progression rates. Am. J. Geriatr. Psychiatry 2011, 19, 951–960. [Google Scholar] [CrossRef] [PubMed]
- Loewenstein, D.A.; Greig, M.T.; Schinka, J.A.; Barker, W.; Shen, Q.; Potter, E.; Raj, A.; Brooks, L.; Varon, D.; Schoenberg, M.; et al. An investigation of PreMCI: Subtypes and longitudinal outcomes. Alzheimer’s Dement. 2012, 8, 172–179. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Jessen, F.; Amariglio, R.E.; Van Boxtel, M.; Breteler, M.; Ceccaldi, M.; Chételat, G.; Glodzik, L.; Dubois, B.; Dufouil, C.; Ellis, K.A.; et al. A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer’s disease. Alzheimer Dement. 2014, 10, 844–852. [Google Scholar] [CrossRef]
- Reisberg, B.; Shulman, M.; Torossian, C.; Leng, L.; Zue, W. Outcome over seven years of healthy adults with and without subjective cognitive impairment. Alzheimer Dement. 2010, 6, 1–27. [Google Scholar] [CrossRef]
- Koppara, A.; Wagner, M.; Lange, C.; Ernst, A.; Wiese, B.; König, H.H.; Brettschneider, C.; Riedel-Heller, S.; Luppa, M.; Weyerer, S.; et al. Cognitive performance before and after the onset of subjective cognitivedecline in old age. Alzheimer Dement. 2015, 1, 194–205. [Google Scholar]
- Ferreira, D.; Falahati, F.; Linden, C.; Buckley, R.F.; Ellis, K.A.; Savage, G.; Villemagne, V.L.; Rowe, C.C.; Ames, D.; Simmons, A.; et al. A “Disease Severity Index” to identify individuals with Subjective Memory Decline who will progress to mild cognitive impairment or dementia. Sci. Rep. 2017, 7, 1–12. [Google Scholar] [CrossRef]
- Jessen, F.; Spottke, A.; Boecker, H.; Brosseron, F.; Buerger, K.; Catak, C.; Janowitz, D.; Fliessbach, K.; Franke, C.; Fuentes, M. Design and first baseline data of the DZNE multicenter observational study on predementia Alzheimer’s disease (DELCODE). Alzheimer Res. Ther. 2018, 10, 15. [Google Scholar] [CrossRef] [PubMed]
- Jessen, F.; Wiese, B.; Bachmann, C.; Eifflaender-Gorfer, S. Prediction of Dementia by Subjective Memory Impairment. Arch. Gen. Psychiatry 2010, 67, 414–422. [Google Scholar] [CrossRef] [PubMed]
- Mitchell, A.J.; Beaumont, H.; Ferguson, D.; Yadegarfar, M.; Stubbs, B. Risk of dementia and mild cognitive impairment in older people with subjective memory complaints: Meta-analysis. Acta Psychiatr. Scand. 2014, 130, 439–451. [Google Scholar] [CrossRef]
- Amariglio, R.E.; Mormino, E.C.; Pietras, A.C.; Marshall, G.A.; Vannini, P.; Johnson, K.A.; Sperling, R.A.; Rentz, D.M. Subjective cognitive concerns, amyloid-β, and neurodegeneration in clinically normal elderly. Neurology 2015, 85, 56–62. [Google Scholar] [CrossRef] [PubMed]
- Buckley, R.F.; Maruff, P.; Ames, D.; Bourgeat, P.; Martins, R.N.; Masters, C.L.; Rainey-Smith, S.; Lautenschlager, N.; Rowe, C.C.; Savage, G.; et al. Subjective memory decline predicts greater rates of clinical progression in preclinical Alzheimer’s disease. Alzheimer Dement. 2016, 12, 796–804. [Google Scholar] [CrossRef] [PubMed]
- Amariglio, R.E.; Buckley, R.F.; Mormino, E.C.; Marshall, G.A.; Johnson, K.A.; Rentz, D.M.; Sperling, R.A. Amyloid-associated increases in longitudinal report of subjective cognitive complaints. Alzheimer’s Dement. 2018, 4, 444–449. [Google Scholar] [CrossRef] [PubMed]
- Slot, R.E.R.; Sikkes, S.A.M.; Berkhof, J.; Brodaty, H.; Buckley, R.; Cavedo, E.; Dardiotis, E.; Guillo-Benarous, F.; Hampel, H.; Kochan, N.A.; et al. Subjective cognitive decline and rates of incident Alzheimer’s disease and non–Alzheimer’s disease dementia. Alzheimer Dement. 2019, 15, 465–476. [Google Scholar] [CrossRef]
- Molinuevo, J.L.; Rabin, L.A.; Amariglio, R.; Buckley, R.; Dubois, B.; Ellis, K.A.; Ewers, M.; Hampel, H.; Klöppel, S.; Rami, L.; et al. Implementation of subjective cognitive decline criteria in research studies. Alzheimer’s Dement. 2017, 13, 296–311. [Google Scholar] [CrossRef]
- Knopman, D.S.; Jack, C.R., Jr.; Wiste, H.J.; Weigand, S.D.; Vemuri, P.; Lowe, V.; Kantarci, K.; Gunter, J.L.; Senjem, M.L.; Ivnik, R.J.; et al. Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease. Neurology 2012, 78, 1576–1582. [Google Scholar] [CrossRef] [Green Version]
- Mormino, E.C.; Papp, K.V.; Rentz, D.M.; Donohue, M.C.; Amariglio, R.; Quiroz, Y.T.; Marshall, G.A.; Donovan, N.; Jackson, J.; Gatchel, J.R.; et al. Early and late change on the preclinical Alzheimer’s cognitive composite in clinically normal older individuals with elevated amyloid β. Alzheimer Dement. 2017, 13, 1004–1012. [Google Scholar] [CrossRef]
- Rabin, L.A.; Smart, C.M.; Crane, P.K.; Amariglio, R.E.; Berman, L.M.; Boada, M.; Buckley, R.F.; Chételat, G.; Dubois, B.; Gifford, K.A.; et al. Subjective Cognitive Decline in Older Adults: An Overview of Self-Report Measures Used Across 19 International Research Studies. J. Alzheimer Dis. 2015, 48, S63–S86. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Wolfsgruber, S.; Polcher, A.; Koppara, A.; Kleineidam, L.; Frölich, L.; Peters, O.; Hüll, M.; Rüther, E.; Wiltfang, J.; Maier, W.; et al. Cerebrospinal Fluid Biomarkers and Clinical Progression in Patients with Subjective Cognitive Decline and Mild Cognitive Impairment. J. Alzheimer Dis. 2017, 58, 939–950. [Google Scholar] [CrossRef] [PubMed]
- Jellinger, K.A.; Attems, J. Neuropathological approaches to cerebral aging and neuroplasticity. Dialogues Clin. Neurosci. 2013, 15, 29–43. [Google Scholar] [PubMed]
- Rijal Upadhaya, A.; Kosterin, I.; Kumar, S.; Von Arnim, C.A.F.; Yamaguchi, H.; Fändrich, M.; Walter, J.; Thal, D.R. Biochemical stages of amyloid-β peptide aggregation and accumulation in the human brain and their association with symptomatic and pathologically preclinical Alzheimer’s disease. Brain 2014, 137, 887–903. [Google Scholar] [CrossRef] [PubMed]
- Serrano-Pozo, A.; Frosch, M.P.; Masliah, E.; Hyman, B.T. Neuropathological alterations in Alzheimer disease. Cold Spring Harb. Perspect. Med. 2011, 1, a006189. [Google Scholar] [CrossRef] [PubMed]
- Kumar, S.; Wirths, O.; Stüber, K.; Wunderlich, P.; Koch, P.; Theil, S.; Rezaei-Ghaleh, N.; Zweckstetter, M.; Bayer, T.A.; Brüstle, O.; et al. Phosphorylation of the amyloid β-peptide at Ser26 stabilizes oligomeric assembly and increases neurotoxicity. Acta Neuropathol. 2016, 131, 525–537. [Google Scholar] [CrossRef] [PubMed]
- Robinson, J.L.; Geser, F.; Corrada, M.M.; Berlau, D.J.; Arnold, S.E.; Lee, V.M.-Y.; Kawas, C.H.; Trojanowski, J.Q. Neocortical and hippocampal amyloid-β and tau measures associate with dementia in the oldest-old. Brain 2011, 134, 3705–3712. [Google Scholar] [CrossRef] [PubMed]
- Boyle, P.A.; Yu, L.; Wilson, R.S.; Schneider, J.A.; Bennett, D.A. Relation of neuropathology with cognitive decline among older persons without dementia. Front. Aging Neurosci. 2013, 5, 1–8. [Google Scholar] [CrossRef] [PubMed]
- Montine, T.J.; Phelps, C.H.; Beach, T.G.; Bigio, E.H.; Cairns, N.J.; Dickson, D.W.; Duyckaerts, C.; Frosch, M.P.; Masliah, E.; Mirra, S.S.; et al. National institute on aging-Alzheimer’s association guidelines for the neuropathologic assessment of Alzheimer’s disease: A practical approach. Acta Neuropathol. 2012, 123, 1–11. [Google Scholar] [CrossRef] [PubMed]
- Thal, D.R.; Beach, T.G.; Zanette, M.; Heurling, K.; Chakrabarty, A.; Ismail, A.; Smith, A.P.; Buckley, C. [18F]flutemetamol amyloid positron emission tomography in preclinical and symptomatic Alzheimer’s disease: Specific detection of advanced phases of amyloid-β pathology. Alzheimer Dement. 2015, 11, 975–985. [Google Scholar] [CrossRef]
- Price, J.L.; McKeel, D.W.; Buckles, V.D.; Roe, C.M.; Xiong, C.; Grundman, M.; Hansen, L.A.; Petersen, R.C.; Parisi, J.E.; Dickson, D.W.; et al. Neuropathology of Nondemented Aging: Presumptive Evidence for Preclinical Alzheimer Disease. Neurobiol. Aging 2009, 30, 1026–1036. [Google Scholar] [CrossRef] [PubMed]
- Riley, K.P.; Jicha, G.A.; Davis, D.; Abner, E.L.; Cooper, G.E.; Stiles, N.; Smith, C.D.; Kryscio, R.J.; Nelson, P.T.; Van Eldik, L.J.; et al. Prediction of Preclinical Alzheimer’s Disease: Longitudinal Rates of Change in Cognition. J. Alzheimer Dis. 2011, 25, 707–717. [Google Scholar] [CrossRef] [PubMed]
- Mufson, E.J.; Malek-Ahmadi, M.; Perez, S.E.; Chen, K. Braak staging, plaque pathology, and APOE status in elderly persons without cognitive impairment. Neurobiol. Aging 2016, 37, 147–153. [Google Scholar] [CrossRef] [PubMed]
- Monsell, S.E.; Mock, C.; Hassenstab, J.; Roe, C.M.; Cairns, N.J.; Morris, J.C.; Kukull, W. Neuropsychological changes in asymptomatic persons with Alzheimer disease neuropathology. Neurology 2014, 83, 434–440. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Jicha, G.A.; Abner, E.L.; Schmitt, F.A.; Kryscio, R.J.; Riley, K.P.; Cooper, G.E.; Stiles, N.; Mendiondo, M.S.; Smith, C.D.; Van Eldik, L.J.; et al. Preclinical AD Workgroup staging: Pathological correlates and potential challenges. Neurobiol. Aging 2012, 33, 1–28. [Google Scholar] [CrossRef] [PubMed]
- Edmonds, E.C.; Bangen, K.J.; Delano-Wood, L.; Nation, D.A.; Furst, A.J.; Salmon, D.P.; Bondi, M.W.; Alzheimer’s Disease Neuroimaging Initiative. Patterns of Cortical and Subcortical Amyloid Burden across Stages of Preclinical Alzheimer’s Disease. J. Int. Neuropsychol. Soc. 2016, 22, 978–990. [Google Scholar] [CrossRef] [PubMed]
- Barnes, L.L.; Schneider, J.A.; Boyle, P.A.; Bienias, J.L.; Bennett, D.A. Memory complaints are related to Alzheimer disease pathology in older persons. Neurology 2006, 67, 1581–1585. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kryscio, R.; Abner, E.; Jicha, G.; Nelson, P.; Smith, C.; Van Eldik, L.; Lou, W.; Fardo, D.; Cooper, G.; Schmitt, F. Self-Reported Memory Complaints: A Comparison of Demented and Unimpaired Outcomes. J. Prev. Alzheimers Dis. 2016, 3, 13–19. [Google Scholar] [CrossRef]
- Kryscio, R.J.; Abner, E.L.; Cooper, G.E.; Fardo, D.W.; Jicha, G.A.; Nelson, P.T.; Schmitt, F.A. Self-reported memory complaints: Implications from a longitudinal cohort with autopsies. Neurology 2014, 83, 1359–1365. [Google Scholar] [CrossRef] [Green Version]
- Schindler, S.E.; Jasielec, M.S.; Weng, H.; Hassenstab, J.J.; Grober, E.; McCue, L.M.; Morris, J.C.; Holtzman, D.M.; Xiong, C.; Fagan, A.M. Neuropsychological measures that detect early impairment and decline in preclinical Alzheimer disease. Neurobiol. Aging 2017, 56, 25–32. [Google Scholar] [CrossRef]
- Vos, S.J.; Xiong, C.; Visser, P.J.; Jasielec, M.S.; Hassenstab, J.; Grant, E.A.; Cairns, N.J.; Morris, J.C.; Holtzman, D.M.; Fagan, A.M. Preclinical Alzheimer’s disease and its outcome: A longitudinal cohort study. Lancet Neurol. 2013, 12, 957–965. [Google Scholar] [CrossRef]
- Edmonds, E.C.; Delano-Wood, L.; Galasko, D.R.; Salmon, D.P.; Bondi, M.W. Subtle Cognitive Decline and Biomarker Staging in Preclinical Alzheimer’s Disease. J. Alzheimer Dis. 2015, 47, 231–242. [Google Scholar] [CrossRef] [PubMed]
- Epelbaum, S.; Genthon, R.; Cavedo, E.; Habert, M.O.; Lamari, F.; Gagliardi, G.; Lista, S.; Teichmann, M.; Bakardjian, H.; Hampel, H.; et al. Preclinical Alzheimer’s disease: A systematic review of the cohorts underlying the concept. Alzheimer Dement. 2017, 13, 454–467. [Google Scholar] [CrossRef] [PubMed]
- Grober, E.; Sanders, A.E.; Hall, C.; Lipton, R.B. Free and Cued Selective Reminding Identifies Very Mild Dementia in Primary Care. Alzheimer Dis. Assoc. Disord. 2010, 24, 284–290. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Papp, K.V.; Rentz, D.M.; Mormino, E.C.; Schultz, A.P.; Amariglio, R.E.; Quiroz, Y.; Johnson, K.A.; Sperling, R.A. Cued memory decline in biomarker-defined preclinical Alzheimer disease. Neurology 2017, 88, 1431–1438. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Tort-Merino, A.; Valech, N.; Peñaloza, C.; Grönholm-Nyman, P.; León, M.; Olives, J.; Estanga, A.; Ecay-Torres, M.; Fortea, J.; Martínez-Lage, P.; et al. Early Detection of Learning Difficulties when Confronted with Novel Information in Preclinical Alzheimer’s Disease Stage 1. J. Alzheimer Dis. 2017, 58, 855–870. [Google Scholar] [CrossRef] [PubMed]
- Rentz, D.M.; Rodriguez, M.A.P.; Amariglio, R.; Stern, Y.; Sperling, R.; Ferris, S. Promising developments in neuropsychological approaches for the detection of preclinical Alzheimer’s disease: A selective review. Alzheimer Res. Ther. 2013, 5, 58. [Google Scholar] [CrossRef] [PubMed]
- Donohue, M.C.; Sperling, R.A.; Salmon, D.P.; Rentz, D.M.; Raman, R.; Thomas, R.G.; Weiner, M.; Aisen, P.S.; Australian Imaging, Biomarkers, and Lifestyle Flagship Study of Ageing; Alzheimer’s Disease Neuroimaging Initiative; et al. The preclinical Alzheimer cognitive composite: Measuring amyloid-related decline. JAMA Neurol. 2014, 71, 961–970. [Google Scholar] [CrossRef]
- Langbaum, J.B.; Hendrix, S.B.; Ayutyanont, N.; Chen, K.; Fleisher, A.S.; Shah, R.C.; Barnes, L.L.; Bennett, D.A.; Tariot, P.N.; Reiman, E.M. An empirically derived composite cognitive test score with improved power to track and evaluate treatments for preclinical Alzheimer’s disease. Alzheimer Dement. 2014, 10, 666–674. [Google Scholar] [CrossRef]
- Lim, Y.Y.; Snyder, P.J.; Pietrzak, R.H.; Ukiqi, A.; Villemagne, V.L.; Ames, D.; Salvado, O.; Bourgeat, P.; Martins, R.N.; Masters, C.L.; et al. Sensitivity of composite scores to amyloid burden in preclinical Alzheimer’s disease: Introducing the Z-scores of Attention, Verbal fluency, and Episodic memory for Nondemented older adults composite score. Alzheimer’s Dement. 2016, 2, 19–26. [Google Scholar] [CrossRef]
- Ayutyanont, N.; Langbaum, J.B.S.; Hendrix, S.B.; Chen, K.; Fleisher, A.S.; Friesenhahn, M.; Ward, M.; Aguirre, C.; Acosta-Baena, N.; Madrigal, L.; et al. The Alzheimer’s Prevention Initiative composite cognitive test score: Sample size estimates for the evaluation of preclinical Alzheimer’s disease treatments in presenilin 1 E280A mutation carriers. J. Clin. Psychiatry 2014, 75, 652–660. [Google Scholar] [CrossRef] [PubMed]
- Buckley, R.F.; Sparks, K.P.; Papp, K.V.; Dekhtyar, M.; Martin, C.; Burnham, S.; Sperling, R.A.; Rentz, D.M. Computerized Cognitive Testing for Use in Clinical Trials: A Comparison of the NIH Toolbox and Cogstate C3 Batteries. J. Prev. Alzheimers Dis. 2017, 4, 3–11. [Google Scholar] [PubMed]
- Sahakian, B.J.; Morris, R.G.; Evenden, J.L.; Heald, A.; Levy, R.; Philpot, M.; Robbins, T.W. A comparative study of visuospatial memory and learning in alzheimer-type dementia and parkinson’s disease. Brain 1988, 111, 695–718. [Google Scholar] [CrossRef] [PubMed]
- De Rover, M.; Pironti, V.A.; McCabe, J.A.; Acosta-Cabronero, J.; Arana, F.S.; Morein-Zamir, S.; Hodges, J.R.; Robbins, T.W.; Fletcher, P.C.; Nestor, P.J.; et al. Hippocampal dysfunction in patients with mild cognitive impairment: A functional neuroimaging study of a visuospatial paired associates learning task. Neuropsychologia 2011, 49, 2060–2070. [Google Scholar] [CrossRef] [PubMed]
- O’Connell, H.; Coen, R.; Kidd, N.; Warsi, M.; Chin, A.V.; Lawlor, B.A. Early detection of Alzheimer’s disease (AD) using the CANTAB Paired Associates Learning Test. Int. J. Geriatr. Psychiatry 2004, 19, 1207–1208. [Google Scholar] [CrossRef] [PubMed]
- Junkkila, J.; Oja, S.; Laine, M.; Karrasch, M. Applicability of the CANTAB-PAL computerized memory test in identifying amnestic mild cognitive impairment and alzheimer’s disease. Dement. Geriatr. Cogn. Disord. 2012, 34, 83–89. [Google Scholar] [CrossRef] [PubMed]
- Soldan, A.; Pettigrew, C.; Moghekar, A.; Albert, M. Computerized cognitive tests are associated with biomarkers of Alzheimer’s disease in cognitively normal individuals 10 years prior. J. Int. Neuropsychol. Soc. 2016, 22, 968–977. [Google Scholar] [CrossRef] [PubMed]
- Nation, D.A.; Ho, J.K.; Dutt, S.; Han, S.D.; Lai, M.H. Neuropsychological Decline Improves Prediction of Dementia Beyond Alzheimer’s Disease Biomarker and Mild Cognitive Impairment Diagnoses. J. Alzheimer Dis. 2019, 69, 1171–1182. [Google Scholar] [CrossRef] [PubMed]
- Crane, P.K.; Carle, A.; Gibbons, L.E.; Insel, P.; Mackin, R.S.; Gross, A.; Jones, R.N.; Mukherjee, S.; Curtis, S.M.; Harvey, D.; et al. Development and assessment of a composite score for memory in the Alzheimer’s Disease Neuroimaging Initiative (ADNI). Brain Imaging Behav. 2012, 6, 502–516. [Google Scholar] [CrossRef] [PubMed]
- Filipek-Gliszczyńska, A.; Barczak, A.; Budziszewska, M.; Mandecka, M.; Gabryelewicz, T.; Barcikowska, M. The Erlangen Score Algorithm in the diagnosis and prediction of the progression from subjective cognitive decline and mild cognitive impairment to Alzheimer-type dementia. Folia Neuropathol. 2018, 56, 88–96. [Google Scholar] [CrossRef] [PubMed]
- Amariglio, R.E.; Donohue, M.C.; Marshall, G.A.; Rentz, D.M.; Salmon, D.P.; Ferris, S.H.; Karantzoulis, S.; Aisen, P.S.; Sperling, R.A.; Alzheimer’s Disease Cooperative Study. Tracking early decline in cognitive function in older individuals at risk for Alzheimer’s disease dementia: The Alzheimer’s Disease Cooperative Study Cognitive Function Instrument HHS Public Access. JAMA Neurol. 2015, 72, 446–454. [Google Scholar] [CrossRef] [PubMed]
- Chipi, E.; Montanucci, C.; Eusebi, P.; D’Andrea, K.; Biscetti, L.; Calabresi, P.; Parnetti, L. The Italian version of Cognitive Function Instrument (CFI) for tracking changes in healthy elderly: Results at 1-year follow-up. Neurol. Sci. 2019. [Google Scholar] [CrossRef] [PubMed]
- Dubois, B.; Epelbaum, S.; Nyasse, F.; Bakardjian, H.; Gagliardi, G.; Uspenskaya, O.; Houot, M.; Lista, S.; Cacciamani, F.; Potier, M.C.; et al. Cognitive and neuroimaging features and brain β-amyloidosis in individuals at risk of Alzheimer’s disease (INSIGHT-preAD): A longitudinal observational study. Lancet Neurol. 2018, 17, 335–346. [Google Scholar] [CrossRef]
- Donohue, M.C.; Sperling, R.A.; Petersen, R.; Sun, C.-K.; Weiner, M.W.; Aisen, P.S. Association between Elevated Brain Amyloid and Subsequent Cognitive Decline Among Cognitively Normal Persons. JAMA 2017, 317, 2305–2316. [Google Scholar] [CrossRef] [PubMed]
- Van Harten, A.C.; Smits, L.L.; Teunissen, C.E.; Visser, P.J.; Koene, T.; Blankenstein, M.A.; Scheltens, P.; van der Flier, W.M. Preclinical AD predicts decline in memory and executive functions in subjective complaints. Neurology 2013, 81, 1409–1416. [Google Scholar] [CrossRef]
- Van Harten, A.C.; Visser, P.J.; Pijnenburg, Y.A.L.; Teunissen, C.E.; Blankenstein, M.A.; Scheltens, P.; van der Flier, W.M. Cerebrospinal fluid Aβ42 is the best predictor of clinical progression in patients with subjective complaints. Alzheimer Dement. 2013, 9, 481–487. [Google Scholar] [CrossRef]
- Molinuevo, J.L.; Blennow, K.; Dubois, B.; Engelborghs, S.; Lewczuk, P.; Perret-Liaudet, A.; Teunissen, C.E.; Parnetti, L. The clinical use of cerebrospinal fluid biomarker testing for Alzheimer’s disease diagnosis: A consensus paper from the Alzheimer’s Biomarkers Standardization Initiative. Alzheimer Dement. 2014, 10, 808–817. [Google Scholar] [CrossRef]
- Blennow, K. A Review of Fluid Biomarkers for Alzheimer’s Disease: Moving from CSF to Blood. Neurol. Ther. 2017, 6, 15–24. [Google Scholar] [CrossRef]
- Adamczuk, K.; Schaeverbeke, J.; Nelissen, N.; Neyens, V.; Vandenbulcke, M.; Goffin, K.; Vandenberghe, R.; Lilja, J.; Hilven, K.; Dupont, P.; et al. Amyloid imaging in cognitively normal older adults: Comparison between 18 F-flutemetamol and 11 C-Pittsburgh compound B. Eur. J. Nucl. Med. Mol. Imaging 2016, 43, 142–151. [Google Scholar] [CrossRef]
- Dumurgier, J.; Hanseeuw, B.J.; Hatling, F.B.; Judge, K.A.; Schultz, A.P.; Chhatwal, J.P.; Blacker, D.; Sperling, R.A.; Johnson, K.A.; Hyman, B.T.; et al. Alzheimer’s Disease Biomarkers and Future Decline in Cognitive Normal Older Adults. J. Alzheimer Dis. 2017, 60, 1451–1459. [Google Scholar] [CrossRef]
- Biscetti, L.; Salvadori, N.; Farotti, L.; Cataldi, S.; Eusebi, P.; Paciotti, S.; Parnetti, L. The added value of Aβ42/Aβ40 in the CSF signature for routine diagnostics of Alzheimer’s disease. Clin. Chim. Acta 2019, 494, 71–73. [Google Scholar] [CrossRef] [PubMed]
- Lewczuk, P.; Matzen, A.; Blennow, K.; Parnetti, L.; Molinuevo, J.L.; Eusebi, P.; Kornhuber, J.; Morris, J.C.; Fagan, A.M. Cerebrospinal Fluid Aβ42/40 Corresponds Better than Aβ42 to Amyloid PET in Alzheimer’s Disease. J. Alzheimer Dis. 2017, 55, 813–822. [Google Scholar] [CrossRef] [PubMed]
- Niemantsverdriet, E.; Valckx, S.; Bjerke, M.; Engelborghs, S. Alzheimer’s disease CSF biomarkers: Clinical indications and rational use. Acta Neurol. Belg. 2017, 117, 591–602. [Google Scholar] [CrossRef] [PubMed]
- Roe, C.M.; Fagan, A.M.; Grant, E.A.; Hassenstab, J.; Moulder, K.L.; Dreyfus, D.M.; Sutphen, C.L.; Benzinger, T.L.; Mintun, M.A.; Holtzman, D.M.; et al. Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5 years later. Neurology 2013, 80, 1784–1791. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Harrington, M.G.; Chiang, J.; Pogoda, J.M.; Gomez, M.; Thomas, K.; Marion, S.D.; Miller, K.J.; Siddarth, P.; Yi, X.; Zhou, F.; et al. Executive Function Changes before Memory in Preclinical Alzheimer’s Pathology: A Prospective, Cross-Sectional, Case Control Study. PLoS ONE 2013, 8, e79378. [Google Scholar] [CrossRef] [PubMed]
- Toledo, J.B.; Zetterberg, H.; Van Harten, A.C.; Glodzik, L.; Martinez-Lage, P.; Bocchio-Chiavetto, L.; Rami, L.; Hansson, O.; Sperling, R.; Engelborghs, S.; et al. Alzheimer’s disease cerebrospinal fluid biomarker in cognitively normal subjects. Brain 2015, 138, 2701–2715. [Google Scholar] [CrossRef] [PubMed]
- Schoonenboom, N.S.M.; Reesink, F.E.; Verwey, N.A.; Kester, M.I.; Teunissen, C.E.; Van De Ven, P.M.; Pijnenburg, Y.A.; Blankenstein, M.A.; Rozemuller, A.J.; Scheltens, P.; et al. Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort. Neurology 2012, 78, 47–54. [Google Scholar] [CrossRef]
- Mandecka, M.; Budziszewska, M.; Barczak, A.; Pepłońska, B.; Chodakowska-Żebrowska, M.; Filipek-Gliszczyńska, A.; Nesteruk, M.; Styczyńska, M.; Barcikowska, M.; Gabryelewicz, T. Association between Cerebrospinal Fluid Biomarkers for Alzheimer’s Disease: APOE Genotypes and Auditory Verbal Learning Task in Subjective Cognitive Decline, Mild Cognitive Impairment, and Alzheimer’s Disease. J. Alzheimer Dis. 2016, 54, 1–12. [Google Scholar] [CrossRef]
- Eckerström, M.; Göthlin, M.; Rolstad, S.; Hessen, E.; Eckerström, C.; Nordlund, A.; Johansson, B.; Svensson, J.; Jonsson, M.; Sacuiu, S.; et al. Longitudinal evaluation of criteria for subjective cognitive decline and preclinical Alzheimer’s disease in a memory clinic sample. Alzheimer’s Dement. 2017, 8, 96–107. [Google Scholar]
- Visser, P.J.; Verhey, F.; Knol, D.L.; Scheltens, P.; Wahlund, L.O.; Freund-Levi, Y.; Tsolaki, M.; Minthon, L.; Wallin, A.K.; Hampel, H.; et al. Prevalence and prognostic value of CSF markers of Alzheimer’s disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: A prospective cohort study. Lancet Neurol. 2009, 8, 619–627. [Google Scholar] [CrossRef]
- Grambaite, R.; Hessen, E.; Auning, E.; Aarsland, D.; Selnes, P.; Fladby, T. Correlates of Subjective and Mild Cognitive Impairment: Depressive Symptoms and CSF Biomarkers. Dement. Geriatr. Cogn. Disord. Extra 2013, 3, 291–300. [Google Scholar] [CrossRef] [PubMed]
- Rizzi, L.; Portal, M.M.; Batista, C.E.A.; Missiaggia, L.; Roriz-Cruz, M. CSF Aβ1–42, but not p-Tau181, differentiates aMCI from SCI. Brain Res. 2018, 1678, 27–31. [Google Scholar] [CrossRef] [PubMed]
- Wolfsgruber, S.; Molinuevo, J.L.; Wagner, M.; Teunissen, C.E.; Rami, L.; Coll-Padrós, N.; Bouwman, F.H.; Slot, R.E.R.; Wesselman, L.M.P.; Peters, O.; et al. Prevalence of abnormal Alzheimer’s disease biomarkers in patients with subjective cognitive decline: Cross-sectional comparison of three European memory clinic samples. Alzheimer Res. Ther. 2019, 11, 8. [Google Scholar] [CrossRef] [PubMed]
- Rami, L.; Fortea, J.; Bosch, B.; Solé-Padullés, C.; Lladó, A.; Iranzo, A.; Sánchez-Valle, R.; Molinuevo, J.L. Cerebrospinal Fluid Biomarkers and Memory Present Distinct Associations along the Continuum from Healthy Subjects to AD Patients. J. Alzheimer Dis. 2011, 23, 319–326. [Google Scholar] [CrossRef] [PubMed]
- Rolstad, S.; Berg, A.I.; Bjerke, M.; Blennow, K.; Johansson, B.; Zetterberg, H.; Wallin, A. Amyloid-β42 is Associated with Cognitive Impairment in Healthy Elderly and Subjective Cognitive Impairment. J. Alzheimer Dis. 2011, 26, 135–142. [Google Scholar] [CrossRef] [PubMed]
- Papp, K.V.; Mormino, E.C.; Amariglio, R.E.; Munro, C.; Dagley, A.; Schultz, A.P.; Johnson, K.A.; Sperling, R.A.; Rentz, D.M. Biomarker validation of a decline in semantic processing in preclinical alzheimer’s disease. Neuropsychology 2016, 30, 624–630. [Google Scholar] [CrossRef]
- Sutphen, C.L.; Jasielec, M.S.; Shah, A.R.; Macy, E.M.; Xiong, C.; Vlassenko, A.G.; Benzinger, T.L.S.; Stoops, E.E.J.; Vanderstichele, H.M.J.; Brix, B.; et al. Longitudinal Cerebrospinal Fluid Biomarker Changes in Preclinical Alzheimer Disease During Middle Age. JAMA Neurol. 2015, 72, 1029–1042. [Google Scholar] [CrossRef] [PubMed]
- Moghekar, A.; Li, S.; Lu, Y.; Li, M.; Wang, M.-C.; Albert, M.; O’Brien, R. CSF biomarker changes precede symptom onset of mild cognitive impairment. Neurology 2013, 81, 1753–1758. [Google Scholar] [CrossRef] [Green Version]
- Stomrud, E.; Minthon, L.; Zetterberg, H.; Blennow, K.; Hansson, O. Longitudinal cerebrospinal fluid biomarker measurements in preclinical sporadic Alzheimer’s disease: A prospective 9-year study. Alzheimer Dement. 2015, 1, 403–411. [Google Scholar] [CrossRef]
- Jansen, W.J.; Ossenkoppele, R.; Knol, D.L.; Tijms, B.M.; Scheltens, P.; Verhey, F.R.J.; Visser, P.J.; Amyloid Biomarker Study Group; Aalten, P.; Aarsland, D.; et al. Prevalence of cerebral amyloid pathology in persons without dementia: A meta-analysis. JAMA 2015, 313, 1924–1938. [Google Scholar] [CrossRef]
- Amariglio, R.E.; Becker, J.A.; Carmasin, J.; Wadsworth, L.P.; Lorius, N.; Sullivan, C.; Maye, J.E.; Gidicsin, C.; Pepin, L.C.; Sperling, R.A.; et al. Subjective cognitive complaints and amyloid burden in cognitively normal older individuals. Neuropsychologia 2012, 50, 2880–2886. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Perrotin, A.; Mormino, E.C.; Madison, C.M.; Hayenga, A.O.; Jagust, W.J. Subjective cognition and amyloid deposition imaging: A Pittsburgh Compound B positron emission tomography study in normal elderly individuals. Arch. Neurol. 2012, 69, 223–229. [Google Scholar] [CrossRef] [PubMed]
- Snitz, B.E.; Lopez, O.L.; McDade, E.; Becker, J.T.; Cohen, A.D.; Price, J.C.; Klunk, W.E.; Mathis, C.A. Amyloid-β imaging in older adults presenting to a memory clinic with subjective cognitive decline: A pilot study. J. Alzheimer Dis. 2015, 48, S151–S159. [Google Scholar] [CrossRef] [PubMed]
- Vannini, P.; Hanseeuw, B.; Munro, C.E.; Amariglio, R.E.; Marshall, G.A.; Rentz, D.M.; Pascual-Leone, A.; Johnson, K.A.; Sperling, R.A. Hippocampal hypometabolism in older adults with memory complaints and increased amyloid burden. Neurology 2017, 88, 1759–1767. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hollands, S.; Lim, Y.Y.; Buckley, R.; Pietrzak, R.H.; Snyder, P.J.; Ames, D.; Ellis, K.A.; Harrington, K.; Lautenschlager, N.; Martins, R.N.; et al. Amyloid-β related memory decline is not associated with subjective or informant rated cognitive impairment in healthy adults. J. Alzheimer Dis. 2015, 43, 677–686. [Google Scholar] [CrossRef] [PubMed]
- Petersen, R.C.; Wiste, H.J.; Weigand, S.D.; Rocca, W.A.; Roberts, R.O.; Mielke, M.M.; Lowe, V.J.; Knopman, D.S.; Pankratz, V.S.; Machulda, M.M.; et al. Association of Elevated Amyloid Levels With Cognition and Biomarkers in Cognitively Normal People From the Community. JAMA Neurol. 2016, 73, 85–92. [Google Scholar] [CrossRef] [PubMed]
- Jansen, W.J.; Ossenkoppele, R.; Tijms, B.M.; Fagan, A.M.; Hansson, O.; Klunk, W.E.; van der Flier, W.M.; Villemagne, V.L.; Frisoni, G.B.; Fleisher, A.S.; et al. Association of cerebral amyloid-β Aggregation with cognitive functioning in persons without dementia. JAMA Psychiatry 2018, 75, 84–95. [Google Scholar] [CrossRef] [PubMed]
- Chételat, G.; Villemagne, V.L.; Pike, K.E.; Ellis, K.A.; Bourgeat, P.; Jones, G.; O’Keefe, G.J.; Salvado, O.; Szoeke, C.; Martins, R.N.; et al. Independent contribution of temporal β-amyloid deposition to memory decline in the pre-dementia phase of Alzheimer’s disease. Brain 2011, 134, 798–807. [Google Scholar] [CrossRef]
- Villemagne, V.L.; Pike, K.E.; Chételat, G.; Ellis, K.A.; Mulligan, R.S.; Bourgeat, P.; Ackermann, U.; Jones, G.; Szoeke, C.; Salvado, O.; et al. Longitudinal Assessment of Aβ and Cognition in Aging and Alzheimer Disease. Ann. Neurol. 2011, 69, 181–192. [Google Scholar] [CrossRef]
- Hedden, T.; Oh, H.; Younger, A.P.; Patel, T.A. Meta-analysis of amyloid-cognition relations in cognitively normal older adults. Neurology 2013, 80, 1341–1348. [Google Scholar] [CrossRef]
- Lim, H.K.; Nebes, R.; Snitz, B.; Cohen, A.; Mathis, C.; Price, J.; Weissfeld, L.; Klunk, W.; Aizenstein, H.J. Regional amyloid burden and intrinsic connectivity networks in cognitively normal elderly subjects. Brain 2014, 137, 3327–3338. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Lim, Y.Y.; Maruff, P.; Pietrzak, R.H.; Ames, D.; Ellis, K.A.; Harrington, K.; Lautenschlager, N.T.; Szoeke, C.; Martins, R.N.; Masters, C.L.; et al. Effect of amyloid on memory and non-memory decline from preclinical to clinical Alzheimer’s disease. Brain 2013, 137, 221–231. [Google Scholar] [CrossRef] [PubMed]
- Timmers, T.; Ossenkoppele, R.; Verfaillie, S.C.; Van Der Weijden, C.W.; Slot, R.E.; Wesselman, L.M.; Windhorst, A.D.; Wolters, E.E.; Yaqub, M.; Prins, N.D.; et al. Amyloid PET and cognitive decline in cognitively normal individuals: The SCIENCe project. Neurobiol. Aging 2019, 79, 50–58. [Google Scholar] [CrossRef] [PubMed]
- Vogel, J.W.; Doležalová, M.V.; La Joie, R.; Marks, S.M.; Schwimmer, H.D.; Landau, S.M.; Jagust, W.J. Subjective cognitive decline and β-amyloid burden predict cognitive change in healthy elderly. Neurology 2017, 89, 2002–2009. [Google Scholar] [CrossRef] [PubMed]
- Ewers, M.; Brendel, M.; Rizk-Jackson, A.; Rominger, A.; Bartenstein, P.; Schuff, N.; Weiner, M.W.; Alzheimer’s Disease Neuroimaging Initiative (ADNI). Reduced FDG-PET brain metabolism and executive function predict clinical progression in elderly healthy subjects. NeuroImage Clin. 2014, 4, 45–52. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Brugnolo, A.; Morbelli, S.; Arnaldi, D.; De Carli, F.; Accardo, J.; Bossert, I.; Dessi, B.; Famà, F.; Ferrara, M.; Girtler, N.; et al. Metabolic correlates of Rey auditory verbal learning test in elderly subjects with memory complaints. J. Alzheimer Dis. 2014, 39, 103–113. [Google Scholar] [CrossRef] [PubMed]
- Matías-Guiu, J.A.; Cabrera-Martín, M.N.; Valles-Salgado, M.; Pérez-Pérez, A.; Rognoni, T.; Moreno-Ramos, T.; Carreras, J.L.; Matías-Guiu, J. Neural Basis of Cognitive Assessment in Alzheimer Disease, Amnestic Mild Cognitive Impairment, and Subjective Memory Complaints. Am. J. Geriatr. Psychiatry 2017, 25, 730–740. [Google Scholar] [CrossRef]
- Scheef, L.; Spottke, A.; Daerr, M.; Joe, A.; Striepens, N.; Kölsch, H.; Popp, J.; Daamen, M.; Gorris, D.; Heneka, M.T.; et al. Glucose metabolism, gray matter structure, and memory decline in subjective memory impairment. Neurology 2012, 79, 1332–1339. [Google Scholar] [CrossRef]
- Shah, T.; Lenzo, N.; Salvado, O.; Taddei, K.; Verdile, G.; Gardener, S.L.; Sohrabi, H.R.; Shen, K.-K.; Rainey-Smith, S.R.; Weinborn, M.; et al. Cerebral Glucose Metabolism is Associated with Verbal but not Visual Memory Performance in Community-Dwelling Older Adults. J. Alzheimer Dis. 2016, 52, 661–672. [Google Scholar]
- Mosconi, L.; De Santi, S.; Brys, M.; Tsui, W.H.; Pirraglia, E.; Glodzik-Sobanska, L.; Zinkowski, R.; Rich, K.E.; Switalski, R.; Mehta, P.D.; et al. Hypometabolism and altered cerebrospinal fluid markers in normal apolipoprotein E E4 carriers with subjective memory complaints. Biol. Psychiatry 2008, 63, 609–618. [Google Scholar] [CrossRef]
- Song, I.U.; Choi, E.; Oh, J.K.; Chung, Y.A.; Chung, S.W. Alteration patterns of brain glucose metabolism: Comparisons of healthy controls, subjective memory impairment and mild cognitive impairment. Acta Radiol. 2016, 57, 90–97. [Google Scholar] [CrossRef] [PubMed]
- Hohman, T.J.; Beason-Held, L.L.; Lamar, M.; Resnick, S.M. Subjective Cognitive Complaints and Longitudinal Changes in Memory and Brain Function. Neuropsychology 2011, 25, 125–130. [Google Scholar] [CrossRef] [PubMed]
- Morbelli, S.; Perneczky, R.; Drzezga, A.; Frisoni, G.B.; Caroli, A.; Van Berckel, B.N.; Ossenkoppele, R.; Guedj, E.; Didic, M.; Brugnolo, A.; et al. Metabolic Networks Underlying Cognitive Reserve in Prodromal Alzheimer Disease: A European Alzheimer Disease Consortium Project. J. Nucl. Med. 2013, 54, 894–902. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Knopman, D.S.; Jack, C.R.; Wiste, H.J.; Weigand, S.D.; Vemuri, P.; Lowe, V.J.; Kantarci, K.; Gunter, J.L.; Senjem, M.L.; Mielke, M.M.; et al. Selective worsening of brain injury biomarker abnormalities in cognitively normal elderly persons with β-amyloidosis. JAMA Neurol. 2013, 70, 1030–1038. [Google Scholar] [CrossRef] [PubMed]
- Dickerson, B.C.; Stoub, T.R.; Shah, R.C.; Sperling, R.A.; Killiany, R.J.; Albert, M.S.; Hyman, B.T.; Blacker, D.; Detoledo-Morrell, L. Alzheimer-signature MRI biomarker predicts AD dementia in cognitively normal adults. Neurology 2011, 76, 1395–1402. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Sabuncu, M.R.; Desikan, R.S.; Sepulcre, J.; Yeo, B.T.T.; Liu, H.; Schmansky, N.J.; Reuter, M.; Weiner, M.W.; Buckner, R.L.; Sperling, R.A.; et al. The dynamics of cortical and hippocampal atrophy in Alzheimer disease. Arch Neurol. 2011, 68, 1040–1048. [Google Scholar] [CrossRef]
- Tondelli, M.; Wilcock, G.K.; Nichelli, P.; De Jager, C.A.; Jenkinson, M.; Zamboni, G. Structural MRI changes detectable up to ten years before clinical Alzheimer’s disease. Neurobiol. Aging 2012, 33, 825.e25–825.e36. [Google Scholar] [CrossRef]
- Peter, J.; Scheef, L.; Abdulkadir, A.; Boecker, H.; Heneka, M.; Wagner, M.; Koppara, A.; Klöppel, S.; Jessen, F. Gray matter atrophy pattern in elderly with subjective memory impairment. Alzheimer Dement. 2014, 10, 99–108. [Google Scholar] [CrossRef]
- Oh, H.; Madison, C.; Villeneuve, S.; Markley, C.; Jagust, W.J. Association of gray matter atrophy with age, β-amyloid, and cognition in aging. Cereb. Cortex 2014, 24, 1609–1618. [Google Scholar] [CrossRef]
- Younes, L.; Albert, M.; Miller, M.I. Inferring changepoint times of medial temporal lobe morphometric change in preclinical Alzheimer’s disease. NeuroImage Clin. 2014, 5, 178–187. [Google Scholar] [CrossRef]
- Schultz, S.A.; Oh, J.M.; Koscik, R.L.; Dowling, N.M.; Gallagher, C.L.; Carlsson, C.M.; Bendlin, B.B.; LaRue, A.; Hermann, B.P.; Rowley, H.A.; et al. Subjective memory complaints, cortical thinning, and cognitive dysfunction in middle-age adults at risk of AD. Alzheimer Dement. 2015, 1, 33–40. [Google Scholar] [CrossRef] [PubMed]
- Chételat, G.; Villemagne, V.L.; Bourgeat, P.; Pike, K.E.; Jones, G.; Ames, D.; Ellis, K.A.; Szoeke, C.; Martins, R.N.; O’Keefe, G.J.; et al. Relationship between atrophy and β-amyloid deposition in Alzheimer disease. Ann. Neurol. 2010, 67, 317–324. [Google Scholar] [PubMed]
- Becker, J.A.; Hedden, T.; Carmasin, J.; Maye, J.; Rentz, D.M.; Putcha, D.; Fischl, B.; Greve, D.N.; Marshall, G.A.; Salloway, S.; et al. Amyloid-β Associated Cortical Thinning in Clinically Normal Elderly. Ann. Neurol. 2011, 69, 1032–1042. [Google Scholar] [CrossRef] [PubMed]
- Dickerson, B.C.; Bakkour, A.; Salat, D.H.; Feczko, E.; Pacheco, J.; Greve, D.N.; Grodstein, F.; Wright, C.I.; Blacker, D.; Rosas, H.D.; et al. The cortical signature of Alzheimer’s disease: Regionally specific cortical thinning relates to symptom severity in very mild to mild AD dementia and is detectable in asymptomatic amyloid-positive individuals. Cereb. Cortex 2009, 19, 497–510. [Google Scholar] [CrossRef] [PubMed]
- Dickerson, B.C.; Wolk, D.A. MRI cortical thickness biomarker predicts AD-like CSF and cognitive decline in normal adults. Neurology 2012, 78, 84–90. [Google Scholar] [CrossRef] [PubMed]
- Raichle, M.E.; MacLeod, A.M.; Snyder, A.Z.; Powers, W.J.; Gusnard, D.A.; Shulman, G.L. A default mode of brain function. Proc. Natl. Acad. Sci. USA 2001, 98, 676–682. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Greicius, M.D.; Krasnow, B.; Reiss, A.L.; Menon, V. Functional connectivity in the resting brain: A network analysis of the default mode hypothesis. Proc. Natl. Acad. Sci. USA 2003, 100, 253–258. [Google Scholar] [CrossRef] [PubMed]
- Greicius, M.D.; Srivastava, G.; Reiss, A.L.; Menon, V. Default-mode network activity distinguishes Alzheimer’s disease from healthy aging: Evidence from functional MRI. Proc. Natl. Acad. Sci. USA 2004, 101, 4637–4642. [Google Scholar] [CrossRef] [PubMed]
- Buckner, R.L.; Andrews-Hanna, J.R.; Schacter, D.L. The brain’s default network: Anatomy, function, and relevance to disease. Ann. N.Y. Acad. Sci. 2008, 1124, 1–38. [Google Scholar] [CrossRef]
- Perrotin, A.; De Flores, R.; Lamberton, F.; Poisnel, G.; La Joie, R.; De La Sayette, V.; Mézenge, F.; Tomadesso, C.; Landeau, B.; Desgranges, B.; et al. Hippocampal Subfield Volumetry and 3D Surface Mapping in Subjective Cognitive Decline. J. Alzheimer Dis. 2015, 48, S141–S150. [Google Scholar] [CrossRef] [PubMed]
- Pegueroles, J.; Vilaplana, E.; Montal, V.; Sampedro, F.; Alcolea, D.; Carmona-Iragui, M.; Clarimon, J.; Blesa, R.; Lleó, A.; Fortea, J.; et al. Longitudinal brain structural changes in preclinical Alzheimer’s disease. Alzheimer Dement. 2017, 13, 499–509. [Google Scholar] [CrossRef] [PubMed]
- Desikan, R.S.; Sabuncu, M.R.; Schmansky, N.J.; Reuter, M.; Cabral, H.J.; Hess, C.P.; Weiner, M.W.; Biffi, A.; Anderson, C.D.; Rosand, J.; et al. Selective disruption of the cerebral neocortex in alzheimer’s disease. PLoS ONE 2010, 5, e12853. [Google Scholar] [CrossRef] [PubMed]
- Desikan, R.S.; McEvoy, L.K.; Thompson, W.; Holland, D.; Roddey, J.C.; Blennow, K.; Aisen, P.S.; Brewer, J.B.; Hyman, B.T.; Dale, A.M. Amyloid-β associated volume loss occurs only in the presence of phospho-tau. Ann. Neurol. 2011, 70, 657–661. [Google Scholar] [CrossRef] [PubMed]
- Pettigrew, C.; Soldan, A.; Sloane, K.; Cai, Q.; Wang, J.; Wang, M.C.; Moghekar, A.; Miller, M.I.; Albert, M.; BIOCARD Research Team. Progressive medial temporal lobe atrophy during preclinical Alzheimer’s disease. NeuroImage Clin. 2017, 16, 439–446. [Google Scholar] [CrossRef] [PubMed]
- Fortea, J.; Sala-Llonch, R.; Bartrés-Faz, D.; Lladó, A.; Solé-Padullés, C.; Bosch, B.; Antonell, A.; Olives, J.; Sanchez-Valle, R.; Molinuevo, J.L.; et al. Cognitively preserved subjects with transitional cerebrospinal fluid ß-amyloid 1-42 values have thicker cortex in Alzheimer’s disease vulnerable areas. Biol. Psychiatry 2011, 70, 183–190. [Google Scholar] [CrossRef] [PubMed]
- Meiberth, D.; Scheef, L.; Wolfsgruber, S.; Boecker, H.; Block, W.; Träber, F.; Erk, S.; Heneka, M.T.; Jacobi, H.; Spottke, A.; et al. Cortical Thinning in Individuals with Subjective Memory Impairment. J. Alzheimer Dis. 2015, 45, 139–146. [Google Scholar] [CrossRef] [PubMed]
- Zhao, W.; Wang, X.; Yin, C.; He, M.; Li, S.; Han, Y. Trajectories of the Hippocampal Subfields Atrophy in the Alzheimer’s Disease: A Structural Imaging Study. Front. Aging Neurosci. 2019, 13, 13. [Google Scholar] [CrossRef] [PubMed]
- Verfaillie, S.C.; Tijms, B.; Versteeg, A.; Benedictus, M.R.; Bouwman, F.H.; Scheltens, P.; Barkhof, F.; Vrenken, H.; Van Der Flier, W.M. Thinner temporal and parietal cortex is related to incident clinical progression to dementia in patients with subjective cognitive decline. Alzheimer Dement. 2016, 5, 43–52. [Google Scholar] [CrossRef] [Green Version]
- Hafkemeijer, A.; Altmann-Schneider, I.; Oleksik, A.M.; Van De Wiel, L.; Middelkoop, H.A.; Van Buchem, M.A.; Van Der Grond, J.; Rombouts, S.A. Increased Functional Connectivity and Brain Atrophy in Elderly with Subjective Memory Complaints. Brain Connect. 2013, 3, 353–362. [Google Scholar] [CrossRef] [PubMed]
- Ryu, S.Y.; Lim, E.Y.; Na, S.; Shim, Y.S.; Cho, J.H.; Yoon, B.; Hong, Y.J.; Yang, D.W. Hippocampal and entorhinal structures in subjective memory impairment: A combined MRI volumetric and DTI study. Int. Psychogeriatr. 2017, 29, 785–792. [Google Scholar] [CrossRef] [PubMed]
- Verfaillie, S.C.J.; Slot, R.E.R.; Dicks, E.; Prins, N.D.; Overbeek, J.M.; Teunissen, C.E.; Scheltens, P.; Barkhof, F.; Van Der Flier, W.M.; Tijms, B.M. A more randomly organized grey matter network is associated with deteriorating language and global cognition in individuals with subjective cognitive decline. Hum. Brain Mapp. 2018, 39, 3143–3151. [Google Scholar] [CrossRef] [PubMed]
- Duke Han, S.; Nguyen, C.P.; Stricker, N.H.; Nation, D.A. Detectable Neuropsychological Differences in Early Preclinical Alzheimer’s Disease: A Meta-Analysis. Neuropsychol. Rev. 2017, 27, 305–325. [Google Scholar] [CrossRef] [PubMed]
Reference | Group (N) | Mean Follow-Up | Biomarker Assessed | % Biomarkers+ (N) | % Progress (N) | Clinical Progression |
---|---|---|---|---|---|---|
Dubois et al. 2018 [73] | SMC (318) | 2 years | Amyloid PET | 28% (88) | 5% (4) | MCI |
Donohue et al. 2017 [74] | CN (445) | 3.1 years | Amyloid PET | 45% (202) | 32% (71) | MCI |
Wolfsgruber et al. 2017 [32] | SCD (82) | 2.3 years | CSF | 24% (20) * | 65% (13) | MCI/dementia |
Van Harten et al. 2013 [75] | SCC (132) | 1.5 years | CSF | 7% (10) * | 60% (6) | MCI/dementia |
Van Harten et al. 2013 [76] | SCC (127) | 3.9 years | CSF | 7% (10) * | 50% (5) | MCI/dementia |
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Chipi, E.; Salvadori, N.; Farotti, L.; Parnetti, L. Biomarker-Based Signature of Alzheimer’s Disease in Pre-MCI Individuals. Brain Sci. 2019, 9, 213. https://doi.org/10.3390/brainsci9090213
Chipi E, Salvadori N, Farotti L, Parnetti L. Biomarker-Based Signature of Alzheimer’s Disease in Pre-MCI Individuals. Brain Sciences. 2019; 9(9):213. https://doi.org/10.3390/brainsci9090213
Chicago/Turabian StyleChipi, Elena, Nicola Salvadori, Lucia Farotti, and Lucilla Parnetti. 2019. "Biomarker-Based Signature of Alzheimer’s Disease in Pre-MCI Individuals" Brain Sciences 9, no. 9: 213. https://doi.org/10.3390/brainsci9090213